Welcome to our dedicated page for bluebird bio news (Ticker: $BLUE), a resource for investors and traders seeking the latest updates and insights on bluebird bio stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect bluebird bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of bluebird bio's position in the market.
Rhea-AI Summary
bluebird bio, Inc. (Nasdaq: BLUE) CEO to Present Corporate Update at J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.52%
Tags
-
Rhea-AI Summary
bluebird bio, Inc. (Nasdaq: BLUE) announced the pricing of its underwritten public offering of 83,333,333 shares of its common stock at a public offering price of $1.50 per share, with expected gross proceeds of $125 million. The company plans to use the net proceeds to support commercialization and manufacturing for its approved gene therapies and for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-45.68%
Tags
-
Rhea-AI Summary
bluebird bio, Inc. (Nasdaq: BLUE) has announced a public offering of $150,000,000 of its common stock, with an option for underwriters to purchase an additional $22,500,000. The offering will support commercialization and manufacturing of its three approved gene therapies, ZYNTEGLO, SKYSONA, and LYFGENIA, as well as fund working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.33%
Tags
Rhea-AI Summary
bluebird bio inc. (NASDAQ: BLUE) presented updated data at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, showing sustained transfusion independence and improvements in iron management in patients with transfusion-dependent beta-thalassemia treated with beti-cel. The data demonstrated durable transfusion independence and a continued positive safety profile in patients through up to nine years of follow-up, reflecting beti-cel's potential as a curative therapy. A total of 63 patients across four clinical studies received beti-cel, with 90.2% of patients in the Phase 3 studies achieving transfusion independence. The safety results following beti-cel treatment largely reflected known side effects, with 19% of patients experiencing beti-cel-related adverse events. Iron management outcomes showed that 69% of patients were able to stop chelation therapy, demonstrating reduced iron management burden in those patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
bluebird bio, Inc. (NASDAQ: BLUE) announced new and updated efficacy, safety, and health-related quality of life data from the Phase 1/2 HGB-206 Group C and Phase 3 HGB-210 studies of lovotibeglogene autotemcel (lovo-cel) gene therapy for sickle cell disease. The data presented at ASH show that lovo-cel has the potential to address the underlying cause of sickle cell disease and provide robust clinical benefits for patients, with 94% complete resolution of sVOEs and 88% complete resolution of VOEs achieved in evaluable patients. The therapy has shown a durable impact on the underlying cause of sickle cell disease, with reductions in VOE frequency and severity, and significant improvements in hemolysis markers and health-related quality of life measures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
bluebird bio, Inc. (NASDAQ: BLUE) announced the U.S. commercial infrastructure for LYFGENIA, an FDA-approved gene therapy for sickle cell disease. LYFGENIA launch includes outcomes-based contract offerings for payers and a personalized patient support program. The wholesale acquisition cost of LYFGENIA is set at $3.1M. The therapy aims to deliver robust and sustained clinical benefits, reducing or eliminating vaso-occlusive events, and enhancing patients' healthcare utilization, future earnings, and life opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-40.54%
Tags
Rhea-AI Summary
bluebird bio, Inc. (Nasdaq: BLUE) has received FDA approval for LYFGENIA™ (lovotibeglogene autotemcel), also known as lovo-cel, for the treatment of sickle cell disease in patients ages 12 and older who have a history of vaso-occlusive events (VOEs). LYFGENIA is a one-time gene therapy that has the potential to resolve vaso-occlusive events and is custom-designed to treat the underlying cause of sickle cell disease. The approval marks bluebird’s third ex vivo gene therapy approved by the FDA for a rare genetic disease and second FDA approval for an inherited hemoglobin disorder, cementing their position as a gene therapy leader.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-40.54%
Tags
-
Rhea-AI Summary
Engine Capital LP, which owns approximately 3% of 2seventy bio, Inc.’s (Nasdaq: TSVT) outstanding shares, believes that the company could be conservatively worth ~$9 per share if it exclusively focuses on its most-valuable asset Abecma, reduces corporate overhead and makes improvements to the composition of the management team and board. The company is currently trading at a market capitalization of just $100 million, despite having a cash balance of $284 million and a 50% profit interest in Abecma that is likely worth at least a few hundred million dollars.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.55%
Tags
-
Rhea-AI Summary
bluebird bio, Inc. (NASDAQ: BLUE) reported continued strong commercial launches for ZYNTEGLO® and SKYSONA®, with 22 patient starts across both programs to date. The company ended the quarter with $227M in cash, cash equivalents, marketable securities, and restricted cash. They also entered into an advance agreement to sell a priority review voucher, if granted, for $103 million, potentially strengthening their cash position. Management will host a conference call at 8:00AM ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.27%
Tags
Rhea-AI Summary
bluebird bio, Inc. will present new long-term efficacy, safety, and health-related quality of life data from its gene therapy programs for sickle cell disease and beta-thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. The data demonstrate sustained improvements in patient outcomes and the maturity of the gene therapies. The company also announced that the FDA accepted the lovo-cel Biologics Licensing Application for Priority Review.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.74%
Tags
bluebird bio, Inc.
Nasdaq:BLUE
BLUE Rankings
BLUE Stock Data
198.52M
108.82M
0.38%
65.11%
15.43%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
United States of America
SOMERVILLE
About BLUE
we are leading the gene therapy revolution. our integrated product platforms encompass gene therapy, cancer immunotherapy and gene editing – providing us with the potential to treat, and hopefully cure, a broad range of serious diseases. we have a lot of energy, and it’s not just the abundance of coffee that keeps us going. find out what sparks our excitement and inspires us every day.